Comparing Selectis Health (OTCMKTS:GBCS) and Embecta (NASDAQ:EMBC)

Embecta (NASDAQ:EMBC) and Selectis Health (OTCMKTS:GBCS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Embecta and Selectis Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	0	3	1	0	2.25
Selectis Health	0	0	0	0	0.00

Embecta currently has a consensus price target of $18.50, indicating a potential upside of 108.10%. Given Embecta’s stronger consensus rating and higher probable upside, equities analysts clearly believe Embecta is more favorable than Selectis Health.

Profitability

This table compares Embecta and Selectis Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Embecta	12.92%	-26.66%	16.06%
Selectis Health	-1.87%	N/A	-2.34%

Risk and Volatility

Embecta has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Selectis Health has a beta of -1.03, suggesting that its stock price is 203% less volatile than the S&P 500.

Earnings and Valuation

This table compares Embecta and Selectis Health”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08 billion	0.49	$95.40 million	$2.37	3.75
Selectis Health	$39.49 million	0.31	-$2.42 million	($0.27)	-15.00

Embecta has higher revenue and earnings than Selectis Health. Selectis Health is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

93.8% of Embecta shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Comparatively, 15.2% of Selectis Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Embecta beats Selectis Health on 12 of the 14 factors compared between the two stocks.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

About Selectis Health

Selectis Health owns and/or operates healthcare facilities in Arkansas, Georgia, Ohio, and Oklahoma, providing a wide array of living services, speech, occupational, physical therapies, social services, and other rehabilitation and healthcare services. Selectis focuses on building strategic relationships with local communities in which its partnership can improve the quality of care for facility residents. With its focused growth strategy, Selectis intends to deepen its American Southcentral and Southeastern market presence to better serve the aging population along a full continuum of care.